J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth ...

Investing.com -- Bayer AG (ETR:BAYGN) on Wednesday reported a 138% jump in quarterly earnings, lifted by higher margins in its Crop Science division and steady growth in new pharmaceuticals, even as ...

The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate ...

CMS announces billions in savings for Medicare when first and second rounds of negotiations go into effect in 2026 and 2027, ...

Shares of Bayer BAYRY gained 12.1% after the Solicitor General supported a Supreme Court review of its Roundup weedkiller ...

Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major bleeding.

The hospital lobby has filed a lawsuit seeking to block the federal government’s 340B Rebate Model Pilot Program, which is ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

The new rule is expected to extend the telemedicine flexibilities through the end of 2026 and will maintain the status quo while the DEA and the Department of Health and Human Services work toward a ...

Medicare Part B costs will rise in 2026. Here's what to expect, including higher prescription drug prices and payment changes that will affect your wallet.

Medicare’s 2026 drug price negotiations under the Inflation Reduction Act aim to lower the cost of expensive medications, ...

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and ...